The Network Pharmacology Company
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.
e-Therapeutics is listed on AIM with the ticker symbol ETX
Ahead of the e-Therapeutics plc AGM on 11 June, acting Chairman and CEO, Professor Malcolm Young, commented on accelerated progress across the business over the last 12 months. The press release can be viewed here.
Progress in ETS2101 Phase Ib Study
e-Therapeutics has announced that the first patient has been enrolled into its phase 1b programme for its cancer drug, ETS2101. More details available here.
Full year results
e-Therapeutics annual report and accounts for the year ended 31 January 2015 has been released. It can be viewed here.
e-Therapeutics has released a trading update for the first six months and further information on its commercial strategy. The press release can be viewed here.